XML 53 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisition of Insight - Schedule of Fair Value of Aggregate Merger Consideration (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended
Jan. 31, 2020
USD ($)
$ / shares
shares
Business Combinations [Abstract]  
Cash consideration $ 7,000 [1]
Shares of Oncocyte common stock issued on the Merger Date | shares 1,915,692 [2]
Closing price per share of Oncocyte common stock on the Merger Date | $ / shares $ 2.61
Market value of Oncocyte common stock issued $ 5,000
Contingent Consideration 11,130 [3]
Total fair value of consideration transferred on the Merger Date $ 23,130
[1] The cash consideration paid on the Merger Date was $6.4 million, which was net of a $0.6 million cash holdback discussed above, recorded as a holdback liability since Oncocyte retained the cash. In accordance with ASC 805, amounts held back for general representations and warranties of the sellers are included as part of the total consideration transferred.
[2] The 229,885 Stock Holdback shares were placed in an escrow account and considered to be issued and outstanding Oncocyte common stock. In accordance with ASC 805, amounts held back for general representations and warranties of the sellers, including escrowed shares of common stock, are included as part of the total consideration transferred.
[3] In accordance with ASC 805, Contingent Consideration, at fair value, is part of the total considered transferred on the Merger Date, as further discussed below.